Report cover image

Systemic Mastocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Sep 30, 2022
Length 51 Pages
SKU # GMD17477748

Description

Systemic Mastocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Drugs In Development, 2022, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4, 2 and 3 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

51 Pages
Introduction
Global Markets Direct Report Coverage
Systemic Mastocytosis – Overview
Systemic Mastocytosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Systemic Mastocytosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Mastocytosis – Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
Allakos Inc
Arog Pharmaceuticals Inc
Blueprint Medicines Corp
Cogent Biosciences Inc
Hoth Therapeutics Inc
Invea Therapeutics Inc
MacroGenics Inc
Seagen Inc
Systemic Mastocytosis – Drug Profiles
avapritinib – Drug Profile
Bezuclastinib – Drug Profile
BLU-263 – Drug Profile
brentuximab vedotin – Drug Profile
crenolanib besylate – Drug Profile
HT-KIT – Drug Profile
INVA-8001 – Drug Profile
lirentelimab – Drug Profile
masitinib – Drug Profile
MGD-024 – Drug Profile
tagraxofusp – Drug Profile
Systemic Mastocytosis – Dormant Projects
Systemic Mastocytosis – Discontinued Products
Systemic Mastocytosis – Product Development Milestones
Featured News & Press Releases
Aug 17, 2022: Analysis Group announces study using real-world evidence to support Blueprint Medicines' AYVAKYT (avapritinib) label expansion for advanced systemic mastocytosis in Europe
Jun 10, 2022: Cogent Biosciences to host investor webcast on June 10, 2022 at 8:00am ET
Jun 10, 2022: Cogent Biosciences announces positive initial clinical data from ongoing phase 2 apex trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM)
Jun 09, 2022: Blueprint Medicines reports continued progress toward goal of transforming treatment of systemic mastocytosis
May 12, 2022: Cogent Biosciences announces presentation at European Hematology Association (EHA) Annual Congress
Apr 11, 2022: Cogent Biosciences presents nonclinical data at AACR Annual Meeting and provides updates on portfolio expansion at R&D Investor Event
Apr 11, 2022: Hoth Therapeutics mRNA frame-shifting therapeutic, HT-KIT, proves effective against aggressive cancer cells
Mar 29, 2022: Cogent Biosciences to host Virtual R&D Investor Event
Mar 25, 2022: Blueprint medicines' AYVAKYT (avapritinib) receives European Commission approval for the treatment of adults with advanced systemic mastocytosis
Mar 11, 2022: Hoth Therapeutics announces Orphan Drug Designation granted to cancer therapeutic HT-KIT to treat Mastocytosis
Mar 08, 2022: Cogent Biosciences announces upcoming presentations at AACR annual meeting 2022
Feb 17, 2022: EMA recommends extension of therapeutic indications for avapritinib
Jan 28, 2022: Blueprint Medicines' AYVAKYT (avapritinib) receives positive CHMP opinion for the treatment of adults with advanced systemic mastocytosis
Jan 19, 2022: AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)
Dec 21, 2021: Hoth Therapeutics announces submission of Orphan Drug Designation Request for HT-KIT to treat Mastocytosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Systemic Mastocytosis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Number of Products by Stage and Target, 2022
Table 5: Number of Products by Stage and Mechanism of Action, 2022
Table 6: Number of Products by Stage and Route of Administration, 2022
Table 7: Number of Products by Stage and Molecule Type, 2022
Table 8: Systemic Mastocytosis – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Table 9: Systemic Mastocytosis – Pipeline by AB Science SA, 2022
Table 10: Systemic Mastocytosis – Pipeline by Allakos Inc, 2022
Table 11: Systemic Mastocytosis – Pipeline by Arog Pharmaceuticals Inc, 2022
Table 12: Systemic Mastocytosis – Pipeline by Blueprint Medicines Corp, 2022
Table 13: Systemic Mastocytosis – Pipeline by Cogent Biosciences Inc, 2022
Table 14: Systemic Mastocytosis – Pipeline by Hoth Therapeutics Inc, 2022
Table 15: Systemic Mastocytosis – Pipeline by Invea Therapeutics Inc, 2022
Table 16: Systemic Mastocytosis – Pipeline by MacroGenics Inc, 2022
Table 17: Systemic Mastocytosis – Pipeline by Seagen Inc, 2022
Table 18: Systemic Mastocytosis – Dormant Projects, 2022
Table 19: Systemic Mastocytosis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Systemic Mastocytosis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us